company background image
5002

Lupin BSE:500257 Stock Report

Last Price

₹696.30

Market Cap

₹316.5b

7D

-5.0%

1Y

-41.4%

Updated

16 May, 2022

Data

Company Financials +
500257 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends3/6

500257 Stock Overview

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally.

Lupin Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lupin
Historical stock prices
Current Share Price₹696.30
52 Week High₹1,267.50
52 Week Low₹678.65
Beta0.67
1 Month Change-9.85%
3 Month Change-8.84%
1 Year Change-41.44%
3 Year Change-8.21%
5 Year Change-44.87%
Change since IPO23,305.04%

Recent News & Updates

Shareholder Returns

500257IN PharmaceuticalsIN Market
7D-5.0%-2.5%-5.1%
1Y-41.4%-11.3%9.7%

Return vs Industry: 500257 underperformed the Indian Pharmaceuticals industry which returned -11.3% over the past year.

Return vs Market: 500257 underperformed the Indian Market which returned 9.7% over the past year.

Price Volatility

Is 500257's price volatile compared to industry and market?
500257 volatility
500257 Average Weekly Movement4.5%
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement7.2%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.7%

Stable Share Price: 500257 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 500257's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196818,573Vinita Guptahttps://www.lupin.com

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women’s health, anti-tuberculosis, and cephalosporin, as well as digital therapeutics platform for doctors and patients. The company is also involved in the provision of biosimilar and over-the-counter products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities.

Lupin Fundamentals Summary

How do Lupin's earnings and revenue compare to its market cap?
500257 fundamental statistics
Market Cap₹316.47b
Earnings (TTM)-₹5.50b
Revenue (TTM)₹163.05b

1.9x

P/S Ratio

-57.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
500257 income statement (TTM)
Revenue₹163.05b
Cost of Revenue₹65.49b
Gross Profit₹97.56b
Other Expenses₹103.06b
Earnings-₹5.50b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 18, 2022

Earnings per share (EPS)-12.09
Gross Margin59.84%
Net Profit Margin-3.37%
Debt/Equity Ratio48.7%

How did 500257 perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

-54%

Payout Ratio

Valuation

Is Lupin undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.65x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: 500257 (₹684.65) is trading above our estimate of fair value (₹608.6)

Significantly Below Fair Value: 500257 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500257 is unprofitable, so we can't compare its PE Ratio to the Indian Pharmaceuticals industry average.

PE vs Market: 500257 is unprofitable, so we can't compare its PE Ratio to the Indian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 500257's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 500257's PB Ratio (2.6x) is in line with the IN Pharmaceuticals industry average.


Future Growth

How is Lupin forecast to perform in the next 1 to 3 years based on estimates from 29 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


106.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500257 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).

Earnings vs Market: 500257 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 500257's is expected to become profitable in the next 3 years.

Revenue vs Market: 500257's revenue (9.5% per year) is forecast to grow slower than the Indian market (12% per year).

High Growth Revenue: 500257's revenue (9.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 500257's Return on Equity is forecast to be low in 3 years time (12.5%).


Past Performance

How has Lupin performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-42.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 500257 is currently unprofitable.

Growing Profit Margin: 500257 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 500257 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.

Accelerating Growth: Unable to compare 500257's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 500257 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Return on Equity

High ROE: 500257 has a negative Return on Equity (-4.44%), as it is currently unprofitable.


Financial Health

How is Lupin's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 500257's short term assets (₹133.2B) exceed its short term liabilities (₹92.4B).

Long Term Liabilities: 500257's short term assets (₹133.2B) exceed its long term liabilities (₹14.0B).


Debt to Equity History and Analysis

Debt Level: 500257's net debt to equity ratio (21.2%) is considered satisfactory.

Reducing Debt: 500257's debt to equity ratio has reduced from 54.7% to 48.7% over the past 5 years.

Debt Coverage: 500257's debt is well covered by operating cash flow (49.9%).

Interest Coverage: 500257's interest payments on its debt are well covered by EBIT (20.7x coverage).


Balance Sheet


Dividend

What is Lupin current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.93%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 500257's dividend (0.95%) is higher than the bottom 25% of dividend payers in the Indian market (0.37%).

High Dividend: 500257's dividend (0.95%) is low compared to the top 25% of dividend payers in the Indian market (1.64%).


Stability and Growth of Payments

Stable Dividend: 500257's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500257's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: 500257 is paying a dividend but the company is unprofitable.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (13.4%), 500257's dividend payments are thoroughly covered by cash flows.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Vinita Gupta (53 yo)

8.67yrs

Tenure

₹127,870,000

Compensation

Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive...


CEO Compensation Analysis

Compensation vs Market: Vinita's total compensation ($USD1.65M) is above average for companies of similar size in the Indian market ($USD610.65K).

Compensation vs Earnings: Vinita's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 500257's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: 500257's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lupin Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Lupin Limited
  • Ticker: 500257
  • Exchange: BSE
  • Founded: 1968
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹316.471b
  • Shares outstanding: 454.50m
  • Website: https://www.lupin.com

Number of Employees


Location

  • Lupin Limited
  • Kalpataru Inspire
  • 3rd Floor
  • Mumbai
  • Maharashtra
  • 400055
  • India

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.